Shares of Neos Therapeutics Inc (NASDAQ:NEOS) have been given an average recommendation of “Hold” by the seven ratings firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $15.50.
A number of equities analysts have weighed in on NEOS shares. ValuEngine lowered Neos Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, May 15th. Zacks Investment Research lowered shares of Neos Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, July 25th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $20.00 price target on shares of Neos Therapeutics in a research report on Wednesday, August 8th. Finally, Wells Fargo & Co reduced their price target on shares of Neos Therapeutics from $14.00 to $11.00 and set a “buy” rating for the company in a research report on Thursday, August 9th.
NASDAQ:NEOS traded up $0.05 during mid-day trading on Tuesday, reaching $5.45. The company’s stock had a trading volume of 4,500 shares, compared to its average volume of 230,864. Neos Therapeutics has a 12-month low of $5.13 and a 12-month high of $13.15. The company has a debt-to-equity ratio of -2.36, a quick ratio of 0.84 and a current ratio of 1.07. The firm has a market cap of $160.24 million, a price-to-earnings ratio of -2.05 and a beta of -0.31.
Neos Therapeutics (NASDAQ:NEOS) last issued its earnings results on Wednesday, August 8th. The company reported ($0.52) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.44) by ($0.08). Neos Therapeutics had a negative return on equity of 586.25% and a negative net margin of 164.40%. The business had revenue of $11.36 million during the quarter, compared to analysts’ expectations of $11.90 million. research analysts predict that Neos Therapeutics will post -1.69 earnings per share for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in NEOS. Quantitative Systematic Strategies LLC purchased a new stake in shares of Neos Therapeutics during the 1st quarter valued at about $123,000. Trexquant Investment LP bought a new position in shares of Neos Therapeutics during the 2nd quarter valued at approximately $131,000. MetLife Investment Advisors LLC bought a new position in shares of Neos Therapeutics during the 4th quarter valued at approximately $134,000. Allianz Asset Management GmbH bought a new position in shares of Neos Therapeutics during the 1st quarter valued at approximately $161,000. Finally, New York State Common Retirement Fund grew its stake in shares of Neos Therapeutics by 38.5% during the 1st quarter. New York State Common Retirement Fund now owns 24,100 shares of the company’s stock valued at $200,000 after acquiring an additional 6,700 shares during the period. 47.47% of the stock is owned by hedge funds and other institutional investors.
About Neos Therapeutics
Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.
Further Reading: Moving Average – How it Helps Investors in Stock Selection
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.